We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Authors
Wollenweber, Tim; Zisser, Lucia; Kretschmer-Chott, Elisabeth; Weber, Michael; Grubmüller, Bernhard; Kramer, Gero; Shariat, Shahrokh F.; Mitterhauser, Markus; Schmitl, Stefan; Vraka, Chrysoula; Haug, Alexander R.; Hacker, Marcus; Hartenbach, Markus; Rasul, Sazan
- Abstract
Background: [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary [ 68Ga]Ga-PSMA-11 ligand PET scan measures such as metabolic volume and SUVmax values of 27 mCRPC men (mean age 71 ± 7 years) before and 4 weeks after receiving three cycles of PSMA-RLT every 4 weeks. Twenty-two patients additionally obtained renal and salivary scintigraphy prior to each cycle. A one-way ANOVA, post-hoc Scheffé test and Cochran’s Q test were applied to assess organ toxicity. Results: In total, 54 PSMA PET scans, 98 kidney, and 98 salivary scintigraphy results were evaluated. There were no significant differences for the ejection fraction, peak time, and residual activity after 5 min for both parotid and submandibular glands prior to each cycle and 4 weeks after the last cycle. Similarly, no significant differences in serum creatinine and renal scintigraphy parameters were observed prior to each cycle and 4 weeks after the last treatment. Despite there being no changes in the metabolic volume of both submandibular glands, SUVmax values dropped significantly (p < 0.05). Conclusion: Results evidenced no alterations in renal function and only minimal impairment of salivary function of mCRPC patients who acquired an intense PSMA-RLT regimen every 4 weeks.
- Subjects
CASTRATION-resistant prostate cancer; POSITRON emission tomography; SALIVARY glands; SUBMANDIBULAR gland; VENTRICULAR ejection fraction
- Publication
Current Oncology, 2021, Vol 28, Issue 5, p3692
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol28050315